Abstract:Abstract Background With the growing prevalence of obesity and its associated metabolic consequences, new strategies for safe and effective weight loss are called for. SGLT2i is a class oral antidiabetic agents that lowers glucose levels through renal glucose loss, with weight reduction as a consequence. Hence, its role in diabetes and obesity is well-recognized. However, its use among individuals without diabetes for safe and durable weight loss has not yet been sufficiently evaluated, although initial studies are promising. Objective To determine the efficacy and safety of SGLT2i compared to placebo among subjects without diabetes mellitus in terms of weight loss and adverse effects. Methods A meta-analysis was conducted on randomized controlled trials (RCTs) comparing different SGLT2i and placebo among patients without diabetes mellitus using RevMan 5.3 software. Results Five trials involving 779 patients met the eligibility criteria. SGLT2i used in these studies include Canagliflozin, Dapagliflozin, Sergliflozin and Remogliflozin with treatment duration ranging from 2 to 26 weeks. Pooled data of these 5 trials showed a significant difference in weight loss among subjects given SGLT2i (MD -1.34 kg [95% CI -1.51, -1.17]; p < 0.00001, I2 = 0%) as compared to placebo. Four studies reported change in BMI as an outcome measure, likewise showing a significant difference favoring the use of SGLT2i (MD -0.50 [95% CI -0.56, -0.44]; p < 0.0001, I2 = 0%). Two RCTs reported the percentage of weight loss. There was a significantly higher proportion of subjects achieving >5% weight loss among those given SGLT2i (RR 1.61 [95% CI 1.09, 2.38]; p = 0.02, I2 = 0%). There was no significant difference in the proportion of subjects who achieved >10% weight loss (RR 1.42 [95% CI 0.60, 3.33]; p = 0.42, I2 = 12%). Urogenital infections were more common in the SGLT2i group (RR 2.62 [95% CI 1.76, 3.91], p < 0.00001, I2 = 0%) as reported in 4 studies. Only one study reported occurrence of hypoglycemia which did not differ significantly between both groups. Conclusion Although this meta-analysis shows a statistically significant decrease in weight (-1.34 kg, [95% CI -1.51, -1.17]) with the use of SGLT2i among subjects without diabetes, this might not be clinically relevant. With the increased risk of urogenital infections with its use, there is insufficient evidence to recommend its routine use as monotherapy for weight loss outside the population of individuals with diabetes. References Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs (2019) 79:219-230.

Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities

Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide‐1‐based therapy

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients

Sodium‑glucose cotransporter‑2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand?

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) Inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic Review and Meta-Analysis

Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists

Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes

Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes

Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes

SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials

Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients